Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Eyes 2022 Japan NDA for Rare Blood Disease Drug on Positive Data
December 14, 2021
- Redasemtide Yields Positive PII Data in Stroke: Shionogi/StemRIM
December 14, 2021
- Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
December 14, 2021
- Daiichi Sankyo’s Valemetostat Logs 48% Response in Japan ATL Study
December 14, 2021
- Takeda Spinout ARTham Now a Kaken Subsidiary
December 14, 2021
- Lilly’s RET Inhibitor, Pfizer’s Oral JAK Drug Make Japan Debut
December 14, 2021
- Chugai Files Actemra for COVID-19 Pneumonia in Japan
December 14, 2021
- J-TEC’s Ocural, Cell Sheet for Eye Disease, Launched in Japan
December 13, 2021
- Mitsubishi Tanabe Eyes US Submission of Oral Edaravone by March-End
December 13, 2021
- Teva Takeda to Roll Out 2nd Blopress AG in January
December 13, 2021
- Novo’s Sogroya Now Available in Japan, Listing Came 10 Months after Approval
December 13, 2021
- Chugai’s Polivy Filed for First-Line DLBCL Treatment in Japan
December 13, 2021
- Takeda Seeks Pediatric Nod for HAE Drug Firazyr in Japan
December 13, 2021
- 7 Companies Launch E Keppra Generics upon Listing
December 13, 2021
- Authorized Generics for Edirol, Vesicare, Vegamox, and More in December Listing
December 10, 2021
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
- Latuda’s Use Patent Dismissed in US; Dainippon Sumitomo Plans to Appeal
December 10, 2021
- Daiichi Sankyo to Speed Up TROP2-Directed ADC Program for Breast Cancer
December 9, 2021
- Opdivo Nabs Top Slot in Japan Sales Ranking in November: Encise
December 9, 2021
- Roche/Chugai’s Tocilizumab Approved for Severe COVID-19 in Europe
December 8, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…